Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28702056 | 0.85 | TDP1 (0.56) | EPHX1TDP1ATMMEN1KMT2A | |
| SCHEMBL21372579 | 0.85 | TDP1 (0.56) | EPHX1TDP1ATMMEN1KMT2A | |
| SCHEMBL2575314 | 0.84 | EPHX1 (0.55) | EPHX1TDP1ATMMEN1KMT2A | |
| SCHEMBL2575317 | 0.84 | TDP1 (0.59) | EPHX1TDP1ATMMEN1KMT2A | |
| SCHEMBL6421718 | 0.83 | TDP1 (0.50) | TDP1ATMMEN1KMT2AACP3 | |
| SCHEMBL5933380 | 0.82 | EPHX1 (0.54) | EPHX1TDP1ATMMEN1KMT2A | |
| SCHEMBL5933367 | 0.82 | EPHX1 (0.54) | EPHX1TDP1ATMMEN1KMT2A | |
| SCHEMBL5077569 | 0.82 | EPHX1 (0.54) | EPHX1TDP1ATMMEN1KMT2A | |
| SCHEMBL1998527 | 0.82 | MEN1 (0.59) | EPHX1TDP1ATMMEN1KMT2A | |
| SCHEMBL487420 | 0.82 | KMT2A (0.55) | EPHX1TDP1ATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972294-B1 | Compounds, their preparation and use | NOVO NORDISK, A/S (DK) | 2005-12-06 | — | — | US | claimed |
| EP-1435352-A2 | 9-[(Substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines | Wyeth Holdings Corporation (US) | 2004-07-07 | — | — | EP | claimed |
| EP-0618190-B1 | 9-[(Substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines | WYETH CORP (US) | 2004-05-19 | — | — | EP | claimed |
| JP-2002542218-A | — | — | 2002-12-10 | — | — | JP | claimed |
| EP-1171414-A1 | COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2002-01-16 | — | — | EP | claimed |
| WO-2000063153-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | claimed |
| US-5371076-A | ANTIBIOTICS | AMERICAN CYANAMID COMPANY (US) | 1994-12-06 | — | — | US | claimed |
| EP-0618190-A1 | 9-[(Substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1994-10-05 | — | — | EP | claimed |
| CN-108697714-B | Fused pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2022-04-26 | — | — | CN | disclosed |
| WO-2019078171-A1 | METHOD FOR CONCENTRATING OR SEPARATING POLYMER COMPOUND | 国立大学法人京都大学 | 2019-04-25 | — | — | WO | disclosed |
| EP-2497475-A1 | Treatment of laminitis with platelet aggregation inhibitors | Dussler, Sabine (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | JITSUOKA MAKOTO (JP) | 2012-06-14 | — | — | US | disclosed |
| US-8158791-B2 | Aza-substituted spiro derivatives | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-0542411-A2 | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation | Sankyo Company Limited (JP) | 1993-05-19 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| US-4927565-A | HYPOTENSIVE AGENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-05-22 | — | — | US | disclosed |
| US-4851387-A | RENIN INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
| EP-0272583-A2 | 5-Substituted amino-4-hydroxy-pentenoic acid derivatives and their use | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-06-29 | — | — | EP | disclosed |
| EP-0264106-A2 | 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | AZI2, NR3C2, DNMT3A | EPHX1 3258/4885TDP1 3743/4885ATM 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.